Andre Artis, MD
Cardiovascular Disease · Merrillville, INNPI 1811987688
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 53 manufacturers reported payments, led by Novartis at 26.2% of the total. Reporting peaked in 2021 at $5,239 and has fallen 69.8% since, to $1,580 in 2025.
Across 417 payments — averaging $40.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4K
- AstraZeneca$2K
- Zimmer Biomet$1K
- Penumbra, Inc.$826
- Bayer$677
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$616
- plus $7K from 47 others
Across 65 payments — averaging $7066.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$159K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$86K
- Merck$66K
- Bayer$65K
- Novartis$55K
- Abbott$29K
What the payments were for
- Consulting fees$4,40026%
- Travel & lodging$2,52215%
- Food & beverage$9,77158%
- Education$1621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LEQVIO$2,772
- FARXIGA$1,628
- Diem2$1,140
- Indigo$826
- TandemLife$355
- ENTRESTO$341
- AFX$302
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$158
- ENDOCROSS Device$129
- Torus Stent Graft System$129
- VERQUVO$114
- MYNX CONTROL VENOUS$106
- Azure$100
How this compares
$16,855 in reported general payments places this provider in the 85th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 22 | $277,579 |
| EntrestoSacubitril/Valsartan | 140 | $196,507 |
| XareltoRivaroxaban | 132 | $143,375 |
| EliquisApixaban | 116 | $123,314 |
| FarxigaDapagliflozin Propanediol | 27 | $34,723 |
| VerquvoVericiguat | 20 | $32,710 |
| BrilintaTicagrelor | 42 | $30,995 |
| Repatha SureclickEvolocumab | 19 | $17,484 |
| Ranolazine ErRanolazine | 84 | $12,564 |
| Metoprolol Succinate | 237 | $2,183 |
| Potassium Chloride | 95 | $1,875 |
| Nitroglycerin | 96 | $1,846 |
| Cilostazol | 108 | $1,765 |
| Rosuvastatin Calcium | 158 | $1,713 |
| Atorvastatin Calcium | 310 | $1,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $677 | $277,57922 claims |
| NovartisEntresto | $4,411 | $196,507140 claims |
| Johnson & JohnsonXarelto | $580 | $143,375132 claims |
| PfizerEliquis | $224 | $123,314116 claims |
| AstraZenecaFarxiga, Brilinta | $2,128 | $65,71769 claims |
| MerckVerquvo | $585 | $32,71020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Merrillville
- Mihas KodencheryMerrillville$20K
- Majd KanbourMerrillville$18K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.